Perioperative immunotherapy a boon for patients with resectable NSCLC: study

Nivolumab pre- and post-surgery led to longer event-free survival and greater pathological response, doctors say.
Rachel Fieldhouse

Adults with resectable non-small cell lung cancer are five times more likely have complete pathological response with perioperative nivolumab plus neoadjuvant chemotherapy compared with chemotherapy alone, oncologists report.

Results from the phase III trial suggest that patients also had significantly longer event-free survival when given the immune checkpoint inhibitor as both neoadjuvant and adjuvant therapy.